Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

L, Rosiñol; A, Oriol; AI, Teruel; D, Hernández; J, López-Jiménez; la Rubia J, de; M, Granell; J, Besalduch; L, Palomera; Y, González; MA, Etxebeste; J, Díaz-Mediavilla; MT, Hernández; Arriba F, de; NC, Gutiérrez; ML, Martín-Ramos; MT, Cibeira; MV, Mateos; J, Martínez; A, Alegre; JJ, Lahuerta; Miguel J, San; J, Bladé

doi:10.1182/blood-2012-02-408922

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. | NobleBlocks